drugset / Trial / NCT04607512

Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects

NCT04607512

Phase 1 Completed 30 enrolled Calithera Biosciences, Inc
RandomizedCrossoverQuadruple-blindOther

Summary

This study is designed to evaluate the effects of telaglenastat on cardiac repolarization (relative to placebo) in healthy adult subjects.

Timeline

Start
2020-10-05
Primary completion
2020-12-30
Completion
2020-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject CB-839 Unknown 800 mg

Indications

No indication recorded.